Novo Nordisk products subject to new US price negotiations
Two Novo Nordisk products are among the ten drugs in the US for which Medicare must renegotiate prices according to new legislation.
The US government must find major price savings for two of Novo Nordisk’s products in the US, among others.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
